Monte Rosa Therapeutics (GLUE) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $9.74, -3.75% vs the prior close of $10.12.
- Volume 883.19K shares, 0.7x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
GLUE slides 3.8% to $9.74, a 6-month low. Closed at $9.74, -3.75% vs the prior close of $10.12. Day range $9.70–$10.23, opened at $10.18.
GLUE daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — GLUE slides 3.8% to $9.74, a 6-month low
- Closed at $9.74, -3.75% vs the prior close of $10.12. Day range $9.70–$10.23, opened at $10.18.
- Volume was 883.19K shares, 0.7x its 50-day average of 1.24M.
- Price is -25.2% vs its 50-day average ($13.01) and -45.5% vs its 200-day average ($17.87).
- 52-week range $8.94–$25.77; today's close sits at 5% of that range, 62.2% below the 52-week high.
Oct 15, 2026 — GLUE rises 2.8% to $10.12
- Closed at $10.12, +2.85% vs the prior close of $9.84. Day range $9.88–$10.24, opened at $9.95.
- Volume was 1.54M shares, 1.2x its 50-day average of 1.25M.
- Price is -22.9% vs its 50-day average ($13.13) and -43.5% vs its 200-day average ($17.90).
- 52-week range $8.94–$25.77; today's close sits at 7% of that range, 60.7% below the 52-week high.
Oct 14, 2026 — GLUE dips 0.5% to $9.84, a 6-month low
- Closed at $9.84, -0.51% vs the prior close of $9.89. Day range $9.71–$10.10, opened at $9.76.
- Volume was 1.09M shares, 0.9x its 50-day average of 1.28M.
- Price is -25.7% vs its 50-day average ($13.24) and -45.1% vs its 200-day average ($17.93).
- 52-week range $8.94–$25.77; today's close sits at 5% of that range, 61.8% below the 52-week high.
Oct 13, 2026 — GLUE slides 6.0% to $9.89 on 2.1x normal volume
- Closed at $9.89, -5.99% vs the prior close of $10.52. Day range $9.85–$10.54, opened at $10.45.
- Volume was 2.71M shares, 2.1x its 50-day average of 1.27M — unusually heavy trading.
- Price is -26.0% vs its 50-day average ($13.37) and -44.9% vs its 200-day average ($17.97).
- 52-week range $8.94–$25.77; today's close sits at 6% of that range, 61.6% below the 52-week high.
Oct 12, 2026 — GLUE rises 2.1% to $10.52
- Closed at $10.52, +2.14% vs the prior close of $10.30. Day range $10.14–$10.63, opened at $10.29.
- Volume was 2.09M shares, 1.5x its 50-day average of 1.38M.
- Price is -21.9% vs its 50-day average ($13.48) and -41.6% vs its 200-day average ($18.00).
- 52-week range $8.52–$25.77; today's close sits at 12% of that range, 59.2% below the 52-week high.
Oct 9, 2026 — GLUE ends flat (-0.2%) to $10.30
- Closed at $10.30, -0.19% vs the prior close of $10.32. Day range $10.21–$10.52, opened at $10.36.
- Volume was 1.20M shares, 0.9x its 50-day average of 1.39M.
- Price is -24.3% vs its 50-day average ($13.60) and -42.9% vs its 200-day average ($18.03).
- 52-week range $7.64–$25.77; today's close sits at 15% of that range, 60.0% below the 52-week high.
Oct 8, 2026 — GLUE rises 1.5% to $10.32
- Closed at $10.32, +1.47% vs the prior close of $10.17. Day range $9.82–$10.38, opened at $10.04.
- Volume was 1.89M shares, 1.4x its 50-day average of 1.38M.
- Price is -25.5% vs its 50-day average ($13.85) and -42.9% vs its 200-day average ($18.06).
- 52-week range $7.43–$25.77; today's close sits at 16% of that range, 60.0% below the 52-week high.
Oct 7, 2026 — GLUE jumps 3.0% to $10.17
- Closed at $10.17, +3.04% vs the prior close of $9.87. Day range $9.68–$10.75, opened at $9.84.
- Volume was 2.08M shares, 1.5x its 50-day average of 1.36M.
- Price is -27.7% vs its 50-day average ($14.07) and -43.8% vs its 200-day average ($18.09).
- 52-week range $7.24–$25.77; today's close sits at 16% of that range, 60.5% below the 52-week high.
Oct 6, 2026 — GLUE slides 3.9% to $9.87, a 6-month low, 4 down days in a row
- Closed at $9.87, -3.89% vs the prior close of $10.27. Day range $9.78–$10.38, opened at $10.38.
- Volume was 1.05M shares, 0.8x its 50-day average of 1.36M.
- Price is -31.0% vs its 50-day average ($14.31) and -45.5% vs its 200-day average ($18.12).
- 52-week range $7.24–$25.77; today's close sits at 14% of that range, 61.7% below the 52-week high.
- That makes 4 straight losses.
Oct 5, 2026 — GLUE dips 2.2% to $10.27, a 6-month low, 3 down days in a row
- Closed at $10.27, -2.19% vs the prior close of $10.50. Day range $10.04–$10.59, opened at $10.56.
- Volume was 1.75M shares, 1.3x its 50-day average of 1.35M.
- Price is -29.5% vs its 50-day average ($14.56) and -43.4% vs its 200-day average ($18.15).
- 52-week range $7.24–$25.77; today's close sits at 16% of that range, 60.1% below the 52-week high.
- That makes 3 straight losses.
Oct 2, 2026 — GLUE slides 6.7% to $10.50, a 6-month low
- Closed at $10.50, -6.75% vs the prior close of $11.26. Day range $10.32–$11.40, opened at $11.40.
- Volume was 2.21M shares, 1.7x its 50-day average of 1.32M.
- Price is -29.1% vs its 50-day average ($14.81) and -42.3% vs its 200-day average ($18.19).
- 52-week range $7.24–$25.77; today's close sits at 18% of that range, 59.3% below the 52-week high.
GLUE latest news & SEC filings
Every SEC filing by or about GLUE in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 6, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Bowen Matthew sold 13 shares at $10.56 (≈$137) on Oct 5, 2026; now holds 25,891
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 1, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Sep 8, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$43.40M (prior year -$12.29M) (loss widened vs Jun 30, 2025)
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 17, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Warmuth Markus sold 9,500 shares at $23.18 (≈$220.21K) on Jul 16, 2026
- Warmuth Markus sold 9,500 shares at $23.18 (≈$220.21K) on Jul 16, 2026
- Warmuth Markus sold 9,500 shares at $23.18 (≈$220.21K) on Jul 16, 2026
- Warmuth Markus sold 9,500 shares at $23.18 (≈$220.21K) on Jul 16, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Jul 16, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Champoux Jennifer sold 4,351 shares at $23.38 (≈$101.73K) on Jul 15, 2026
- Champoux Jennifer sold 4,351 shares at $23.38 (≈$101.73K) on Jul 15, 2026
- Champoux Jennifer sold 4,351 shares at $23.38 (≈$101.73K) on Jul 15, 2026
- Champoux Jennifer sold 4,351 shares at $23.38 (≈$101.73K) on Jul 15, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Jul 16, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Jul 15, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Jul 8, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 7, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Townson Sharon sold 400 shares at $24.13 (≈$9.65K) on Jul 6, 2026
- Townson Sharon sold 5,600 shares at $23.25 (≈$130.20K) on Jul 6, 2026
- Townson Sharon sold 400 shares at $24.13 (≈$9.65K) on Jul 6, 2026
- Townson Sharon sold 5,600 shares at $23.25 (≈$130.20K) on Jul 6, 2026
- Townson Sharon sold 400 shares at $24.13 (≈$9.65K) on Jul 6, 2026
- Townson Sharon sold 5,600 shares at $23.25 (≈$130.20K) on Jul 6, 2026
- …plus 2 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Jul 6, 2026 · Form SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade GLUE
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Mar 17, 2026, Nov 6, 2025. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.61% (largest 6.7%).
- Liquidity: about 1.45M shares (≈$14.16M) trade per day on average.
- 52-week position: $9.74 vs a range of $8.94–$25.77 (5% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Markus Warmuth sold 9,500 shares on Jul 16, 2026.
- Latest filings: 8-K Oct 1, 2026; 8-K Sep 8, 2026; 10-Q Aug 6, 2026.
- Share count: 85.31M shares outstanding (Jul 31, 2026), +38.1% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
GLUE market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 10.18 | 10.23 | 9.70 | 9.74 | 883.19K |
| Oct 15, 2026 | 9.95 | 10.24 | 9.88 | 10.12 | 1.54M |
| Oct 14, 2026 | 9.76 | 10.10 | 9.71 | 9.84 | 1.09M |
| Oct 13, 2026 | 10.45 | 10.54 | 9.85 | 9.89 | 2.71M |
| Oct 12, 2026 | 10.29 | 10.63 | 10.14 | 10.52 | 2.09M |
| Oct 9, 2026 | 10.36 | 10.52 | 10.21 | 10.30 | 1.20M |
| Oct 8, 2026 | 10.04 | 10.38 | 9.82 | 10.32 | 1.89M |
| Oct 7, 2026 | 9.84 | 10.75 | 9.68 | 10.17 | 2.08M |
| Oct 6, 2026 | 10.38 | 10.38 | 9.78 | 9.87 | 1.05M |
| Oct 5, 2026 | 10.56 | 10.59 | 10.04 | 10.27 | 1.75M |
| Oct 2, 2026 | 11.40 | 11.40 | 10.32 | 10.50 | 2.21M |
| Oct 1, 2026 | 12.15 | 12.26 | 11.07 | 11.26 | 2.87M |
| Sep 30, 2026 | 11.85 | 12.15 | 11.65 | 11.93 | 914.00K |
| Sep 29, 2026 | 11.68 | 12.17 | 11.56 | 11.74 | 545.10K |
| Sep 28, 2026 | 11.69 | 11.98 | 11.50 | 11.71 | 772.40K |
| Sep 25, 2026 | 11.75 | 11.89 | 11.61 | 11.77 | 802.10K |
| Sep 24, 2026 | 11.93 | 11.99 | 11.41 | 11.72 | 1.14M |
| Sep 23, 2026 | 12.60 | 12.61 | 11.70 | 11.89 | 1.18M |
| Sep 22, 2026 | 12.35 | 12.73 | 12.21 | 12.60 | 1.21M |
| Sep 21, 2026 | 12.20 | 12.31 | 12.06 | 12.26 | 1.13M |
About Monte Rosa Therapeutics
Monte Rosa Therapeutics (GLUE) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in BOSTON, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1826457.
GLUE board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Ali Behbahani | Director | Jul 6, 2026 |
| Kimberly Blackwell | Director | Jun 12, 2026 |
| Eric A Hughes | Director | Jun 12, 2026 |
| Anthony M. Manning | Director | Jun 30, 2026 |
| Andrew N Schiff | Director | Jun 12, 2026 |
| Christine Siu | Director | Jun 12, 2026 |
| Jan Skvarka | Director | Jun 12, 2026 |
| Markus Warmuth | President & CEO | Jul 17, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Matthew Bowen | Principal Accounting Officer | Apr 7, 2026 |
| Jennifer Champoux | Chief Operating Officer | Jul 16, 2026 |
| Edmund Dunn | Principal Accounting Officer | Mar 5, 2026 |
| Filip Janku | Chief Medical Officer | Jul 1, 2026 |
| Philip Nickson | Chief Business & Legal Officer | Apr 10, 2026 |
| Sharon Townson | Chief Scientific Officer | Jul 7, 2026 |
| Markus Warmuth | President & CEO | Jul 17, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 16, 2026 | Markus Warmuth | Sale | 9,500 | $23.18 |
| Jul 16, 2026 | Markus Warmuth | Sale | 9,500 | $23.18 |
| Jul 16, 2026 | Markus Warmuth | Sale | 9,500 | $23.18 |
| Jul 16, 2026 | Markus Warmuth | Sale | 9,500 | $23.18 |
| Jul 15, 2026 | Jennifer Champoux | Sale | 4,351 | $23.38 |
| Jul 15, 2026 | Jennifer Champoux | Sale | 4,351 | $23.38 |
| Jul 15, 2026 | Jennifer Champoux | Sale | 4,351 | $23.38 |
| Jul 15, 2026 | Jennifer Champoux | Sale | 4,351 | $23.38 |
| Jul 6, 2026 | Sharon Townson | Sale | 400 | $24.13 |
| Jul 6, 2026 | Sharon Townson | Sale | 5,600 | $23.25 |
| Jul 6, 2026 | Sharon Townson | Sale | 400 | $24.13 |
| Jul 6, 2026 | Sharon Townson | Sale | 5,600 | $23.25 |
| Jul 6, 2026 | Sharon Townson | Sale | 400 | $24.13 |
| Jul 6, 2026 | Sharon Townson | Sale | 5,600 | $23.25 |
| Jul 6, 2026 | Sharon Townson | Sale | 400 | $24.13 |
GLUE financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-38.63M | — | $-22.80M |
| Dec 31, 2024 | — | $-72.70M | — | $42.00M |
| Dec 31, 2023 | — | $-135.35M | — | $-43.80M |
| Dec 31, 2022 | — | $-108.50M | — | $-92.47M |
| Dec 31, 2021 | — | $-73.96M | — | $-59.36M |
Latest balance sheet: total assets $691.16M, total liabilities $203.88M, cash $90.10M (as of Jun 30, 2026).
GLUE earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $15.71 |
| May 7, 2026 | 8-K Item 2.02 (results) | $19.81 |
| Mar 17, 2026 | 8-K Item 2.02 (results) | $16.03 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $13.01 |
| Aug 7, 2025 | 8-K Item 2.02 (results) | $4.23 |
| May 8, 2025 | 8-K Item 2.02 (results) | $4.22 |
| Mar 20, 2025 | 8-K Item 2.02 (results) | $7.06 |
| Jan 10, 2025 | 8-K Item 2.02 (results) | $5.70 |
| Nov 7, 2024 | 8-K Item 2.02 (results) | $9.53 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| May 9, 2024 | 8-K Item 2.02 (results) | — |
| Mar 14, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Revolution Medicines (RVMD)Argenx Se (ARGX)Kodiak Sciences (KOD)Greenland Mines (GRML)Halozyme Therapeutics (HALO)Biogen (BIIB)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on GLUE
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.